Healthy Returns: Employers aren't expanding coverage of GLP-1 obesity drugs
5 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"Healthy Returns: Employers aren't expanding coverage of GLP-1 obesity drugs" is generating significant coverage in the Health category, with 5 articles from 5 distinct sources tracked by PULSE so far.
Outlets currently covering the story include CFO.com, Darwin Nutrition, The Globe and Mail and The Union Democrat. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 51d ago.
Quick answers
Why is "Healthy Returns: Employers aren't expanding coverage of GLP-1 obesity drugs" trending?
Because 5 independent news sources published 5 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (10)
- As many Mass. residents face losing access to GLP-1s, local researchers dig into mental, physical impacts The Bay State Banner · 51d ago
- As Employers Drop Obesity Drug Coverage, Hims & Hers Could Be the Winner The Globe and Mail · 51d ago
- GLP-1 Access Depends on Smarter Benefit Design and Patient Support Pharmacy Times – Pharmacy Practice News and Expert Insights · 51d ago
- Soaring demand for GLP-1 drugs strains city budgets in North Texas, causing cuts WFAA · 51d ago
- Medicaid drops GLP-1 coverage for tens of thousands in Mass., including children The Boston Globe · 51d ago
- High cost of GLP-1 drugs tries companies’ patience CFO.com · 51d ago
- Ozempic and GLP-1 reimbursement in 2026: who is eligible? Darwin Nutrition · 51d ago
- As Employers Drop Obesity Drug Coverage, Hims & Hers Could Be the Winner The Globe and Mail · 51d ago
- Trouble getting weight loss drugs covered by insurance? Here’s what to know The Union Democrat · 51d ago
- Healthy Returns: Employers aren't expanding coverage of GLP-1 obesity drugs CNBC · 51d ago
Topics
Related trends
A Cardiologist’s No. 1 Rule for Healthy Eating Is Avoiding This Food: ‘I Don’t Touch It’
4 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
New weight loss drug may burn fat without muscle loss seen in GLP-1 drugs
1 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
Ozempic may help people with serious mental health condition: study
Ozempic, a popular weight‑loss drug, is now being linked to benefits for serious mental illnesses such as bipolar disorder.
The Medicare GLP-1 Discount Has One Big Catch: Some Sick Patients Don’t Qualify
7 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
‘Outer Banks’ Returns To Netflix With Middling Viewership For Final Season; ‘Tires’ Hits Series-High Ranking
4 news sources are covering this Entertainment story right now — PULSE is tracking how fast it spreads.
Are GLP-1 Drugs a ‘Fountain of Youth’? Doctors Explain Health Benefits Beyond Weight Loss
9 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.